燕燕;李艾帆;

• 1:郑州市第一人民医院

摘要(Abstract)：

目的探讨磷酸化牛磺酸(p-Tau)、α-突触核蛋白在阿尔茨海默病(AD)患者脑脊液中表达的意义,分析其与AD病情程度的相关性。方法选取2015-01—2019-08郑州市第一人民医院收治的149例AD患者,采用简易精神状态量表(MMSE)评估AD病情严重程度,根据MMSE评分分为轻中度组和重度组。比较2组脑脊液p-Tau、α-突触核蛋白表达水平,对比可能导致AD病情加重的相关因素,采用Logistic回归分析导致AD病情加重的危险因素,采用Pearson相关系数法分析脑脊液p-Tau、α-突触核蛋白水平与MMSE评分的相关性。结果重度组MMSE评分显著低于轻中度组,脑脊液p-Tau、α-突触核蛋白表达水平显著高于轻中度组,差异有统计学意义(P<0.05)。经Logistic回归分析高血压(OR=2.077,95%CI:1.785～2.369,P<0.001)、糖尿病(OR=3.323,95%CI:2.878～3.769,P<0.001)、痴呆家族史(OR=2.499,95%CI:1.748～3.251,P=0.002)、脑脊液p-Tau(OR=2.389,95%CI:1.236～3.543,P=0.002)、α-突触核蛋白(OR=2.492,95%CI:2.197～2.787,P=0.001)均是导致重度AD的危险因素。Pearson相关性分析示AD患者脑脊液中p-Tau蛋白水平与MMSE评分呈负相关(r=-0.816,P<0.001),α-突触核蛋白浓度与MMSE评分呈负相关(r=-0.735,P<0.001)。结论脑脊液p-Tau、α-突触核蛋白是导致重度AD的危险因素,两者表达水平随AD患者病情严重程度增加而升高,与MMSE评分呈负相关。

关键词(KeyWords)： 阿尔茨海默病;磷酸化牛磺酸;α-突触核蛋白;脑脊液

Abstract:

Keywords:

基金项目(Foundation): 河南省科技发展计划(编号:192102310052)

作者(Authors): 燕燕;李艾帆;

参考文献(References)：

• [1] YANG H,WANG W,JIA L,et al.The Effect of Chronic Cerebral Hypoperfusion on Blood-Brain Barrier Permeability in a Transgenic Alzheimer's Disease Mouse Model (PS1V97L)[J].J Alzheimers Dis,2020,74(1):261-275.DOI:10.3233/JAD-191045.
• [2] BAGHEL V,TRIPATHI M,PARIDA G,et al.In Vivo Assessment of Tau Deposition in Alzheimer Disease and Assessing Its Relationship to Regional Brain Glucose Metabolism and Cognition[J].Clin Nucl Med,2019,44(11):e597-e601.DOI:10.1097/RLU.0000000000002791.
• [3] REY N L,BOUSSET L,GEORGE S,et al.α-Synuclein conformational strains spread,seed and target neuronal cells differentially after injection into the olfactory bulb[J].Acta Neuropathol Commun,2019,7(1):221.DOI:10.1186/s40478-019-0859-3.
• [4] 郑伟,林敬源,林小娟.阿尔茨海默病早期快速筛查的简易风险评估模型探索[J].中国实用神经疾病杂志,2019,22(18):1981-1987.DOI:10.12083/SYSJ.2019.18.331.
• [5] HEYANKA D J,MACKELPRANG J L,GOLDEN C J,et al.Distinguishing Alzheimer's disease from vascular dementia:an exploration of five cognitive domains[J].Int J Neurosci,2010,120(6):409-414.DOI:10.3969/j.issn.1002-266X.2013.03.037.
• [6] MCKHANN G M,KNOPMAN D S,CHERTKOW H,et al.The diagnosis of dementia due to Alzheimer's disease:recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease[J].Alzheimers Dement,2011,7(3):263-269.DOI:10.1016/j.jalz.2011.03.005.
• [7] 井初雅,井长信,方杰,等.神经免疫在阿尔茨海默病中的作用研究进展[J].中国实用神经疾病杂志,2019,22(3):330-336.DOI:10.12083/SYSJ.2019.03.060.
• [8] 周彦均,黄南渠,巴智胜,等.自噬在阿尔兹海默病发病机制中的作用[J].中国实用神经疾病杂志,2019,22(12):1388-1392.DOI:10.12083/SYSJ.2019.12.196.
• [9] GRIFFITHS J,THAIKRUEA L,WONGPAKARAN N,et al.Prevalence of Mild Cognitive Impairment in Rural Thai Older People,Associated Risk Factors and their Cognitive Characteristics[J].Dement Geriatr Cogn Dis Extra,2020,10(1):38-45.DOI:10.1159/000506279.
• [10] WEISSBERGER G H,GOLLAN T H,BONDI M W,et al.Neuropsychological Deficit Profiles,Vascular Risk Factors,and Neuropathological Findings in Hispanic Older Adults with Autopsy-Confirmed Alzheimer's Disease[J].J Alzheimers Dis,2019,67(1):291-302.DOI:10.3233/JAD-180351.
• [11] WELDON FURR J,MORALES-SCHEIHING D,MANWANI B,et al.Cerebral Amyloid Angiopathy,Alzheimer's Disease and MicroRNA:miRNA as Diagnostic Biomarkers and Potential Therapeutic Targets[J].Neuromolecular Med,2019,21(4):369-390.DOI:10.1007/s12017-019-08568-0.
• [12] ORTEGA R L,DAKTERZADA F,ARIAS A,et al.Usefulness of CSF Biomarkers in Predicting the Progression of Amnesic and Nonamnesic Mild Cognitive Impairment to Alzheimer's Disease[J].Curr Aging Sci,2019,12(1):35-42.DOI:10.2174/18746098126661901 12095430.
• [13] WEGMANN S.Liquid-Liquid Phase Separation of Tau Protein in Neurobiology and Pathology[J].Adv Exp Med Biol,2019,1184:341-357.DOI:10.1007/978-98132-9358-8_25.
• [14] VIODé A,EPELBAUM S,BENYOUNES I,et al.Simultaneous quantification of Tau and α-synuclein incerebrospinal fluid by high-resolution mass spectro-metry for differentiation of Lewy Body Dementia from Alzheimer's Disease and controls[J].Analyst,2019,144(21):6342-6351.DOI:10.1039/c9an00751b.
• [15] BASSIL F,BROWN H J,PATTABHIRAMAN S,et al.Amyloid-Beta (Aβ) Plaques Promote Seeding and Spreading of Alpha-Synuclein and Tau in a Mouse Model of Lewy Body Disorders with Aβ Pathology[J].Neuron,2020,105(2):260.e6-275.e6.DOI:10.1016/j.neuron.2019.10.010.
• [16] SHI Y,GU L,WANG Q,et al.Platelet Amyloid-β Protein Precursor (AβPP) Ratio and Phosphorylated Tau as Promising Indicators for Early Alzheimer's Disease[J].J Gerontol A Biol Sci Med Sci,2020,75(4):664-670.DOI:10.1093/gerona/glz005.
• [17] RADANOVIC M,OSHIRO C A,FREITAS T Q,et al.Correlation between CSF biomarkers of Alzheimer's disease and global cognition in a psychogeriatric clinic cohort[J].Braz J Psychiatry,2019,41(6):479-484.DOI:10.1590/1516-4446-2018-0296.
• [18] 许昱琛,桑子玚,阎思伯,等.乳铁蛋白对APP/PS1转基因小鼠神经病理的抑制作用[J].中国实用神经疾病杂志,2020,23(5):369-373.DOI:10.12083/SYSJ.2020.05.193.
• [19] VAN STEENOVEN I,MAJBOUR N K,VAIKATH N N,et al.α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies[J].Mov Disord,2018,33(11):1724-1733.DOI:10.1002/mds.111.
• [20] WATTMO C,BLENNOW K,HANSSON O.Cerebro-spinal fluid biomarker levels:phosphorylated Tau (T) and total Tau (N) as markers for rate of progression in Alzheimer's disease[J].BMC Neurol,2020,20(1):10.DOI:10.1186/s12883-019-1591-0.
• [21] KRANCE S H,COGO-MOREIRA H,RABIN J S,et al.Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression:An Empirical Model[J].J Neurosci,2019,39(37):7428-7437.DOI:10.1523/JNEUROSCI.1056-19.2019.
• [22] DOLATSHAHI M,POURMIRBABAEI S,KAMALIAN A,et al.Longitudinal Alterations of Alpha-Synuclein,Amyloid Beta,Total,and Phosphorylated Tau in Cerebrospinal Fluid and Correlations Between Their Changes in Parkinson's Disease[J].Front Neurol,2018,9:560.DOI:10.3389/fneur.2018.00560.
• [23] CAO C,HASEGAWA Y,HAYASHI K,et al.Chronic Angiotensin 1-7 Infusion Prevents Angiotensin-II-Induced Cognitive Dysfunction and Skeletal Muscle Injury in a Mouse Model of Alzheimer's Diseas e[J].J Alzheimers Dis,2019,69(1):297-309.DOI:10.3233/JAD-181000.
• [24] MARTINEZ-VALBUENA I,VALENTI-AZCARATE R,AMAT-VILLEGAS I,et al.Amylin as a potential link between type 2 diabetes and alzheimer disease[J].Ann Neurol,2019,86(4):539-551.DOI:10.1002/ana.25570.
• [25] 周雪莹,徐武华.脑内淋巴引流和Aβ清除机制对阿尔茨海默病防治的研究进展[J].中国实用神经疾病杂志,2020,23(9):822-825.DOI:10.12083/SYSJ.2020.09.132.
• [26] CHEN X Q,SALEHI A,PEARN M L,et al.Targeting increased levels of APP in Down syndrome:Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model[J].Alzheimers Dement,2020 Sep 25.DOI:10.1002/alz.12185.
• [27] HANES J,KOVAC A,KVARTSBERG H,et al.Evaluation of a novel immunoassay to detect p-Tau Thr127 in the CSF to distinguish Alzheimer disease from other dementias[J].Neurology,2020 Sep 24:10.1212/WNL.0000000000010814.DOI:10.1212/WNL.0000000000 010814.
• [28] NARAYANAN S E,SEKHAR N,RAJAMMA R G,et al.Exploring the Role of Aggregated Proteomes in the Pathogenesis of Alzheimer's Disease[J].Curr Protein Pept Sci,2020 Sep 21.DOI:10.2174/138920372166620 0921152246.
• [29] WATERMEYER T,MARROIG A,RITCHIE C W,et al.Cognitive Dispersion is not Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease:Results from the European Prevention of Alzheimer's Dementia (EPAD) v500.0 Cohort[J].J Alzheimers Dis,2020 Sep 11.DOI:10.3233/JAD-200514.
• [30] ZHAO A,LI Y,DENG Y,et al.TNF receptors are associated with tau pathology and conversion to Alzheimer's dementia in subjects with mild cognitive impairment[J].Neurosci Lett,2020 Sep 15:135392.DOI:10.1016/j.neulet.2020.135392.
• [31] AGNELLO L,GAMBINO C M,LO SASSO B,et al.Neurogranin as a Novel Biomarker in Alzheimer's Disease[J].Lab Med,2020 Sep 14:lmaa062.DOI:10.1093/labmed/lmaa062.
• [32] COUGHLIN D G,ITTYERAH R,PETERSON C,et al.Hippocampal subfield pathologic burden in Lewy body diseases vs.Alzheimer's disease[J].Neuropathol Appl Neurobiol,2020 Sep 6.DOI:10.1111/nan.12659.
• [33] LEE E Y,SRINIVASAN Y,DE ANDA J,et al.Functional Reciprocity of Amyloids and Antimicrobial Peptides:Rethinking the Role of Supramolecular Assembly in Host Defense,Immune Activation,and Inflammation[J].Front Immunol,2020,11:1629.DOI:10.3389/fimmu.2020.01629.